RGRaghubir Gole

Raghubir Gole

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Raghubir Gole has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessment of Likelihood Ratio of the Medicines Enlisted under the Rubric “Pain, Knee, Motion, Amelioration” in the Extremities Chapter of Kent's Repertory

    by Urmi Roy, Rajat K. Pal, Subhranil Saha, Sk Monsur Alam, Munmun Koley, Raghubir Gole, Sumana Sengupta, Quamar Sultana, Usashi Nag, Mousumi Koley, et al.

    “Pain, Knee, Motion, Amelioration” in the Extremities chapter of Kent's repertory with 20 enlisted medicines is one of the most frequently encountered rubrics in homeopathy but has not been evaluated systematically. Bayesian statistics resulting in the likelihood ratio (LR) could offer a better evaluation of the enlisted medicines as well as the eligibility of other medicines. An analytical, epidemiological, longitudinal outcome study was conducted in different outpatient departments of D.N. De Homoeopathic Medical College and Hospital, Kolkata, on 1,204 patients over 18 months using ORIDL (Outcome Related to Impact on Daily Living), whose scale ranges from +4 to −4. Results were documented during each follow-up, continuing until the most recent visit at an average of 3 months. The LRs were reported with their corresponding 95% confidence intervals (CIs). Analysis included 1,204 cases with 20 enlisted medicines and 37 not enlisted homeopathic medicines. The prevalence of the rubric “Pain, Knee, Motion, Amelioration” was 18.8%. Among the enlisted ones, the medicines having LR ≥ 1.5 were Calcarea carbonicum LR(+) 1.7 (95% CI: 0.8 to 3.5) and Rhus toxicodendron LR(+) 2.3 (95% CI: 1.7 to 3.1). Some medicines with LR ≥ 1.5 that were not previously enlisted in the rubric were Arnica montana LR(+) 2.0 (95% CI: 0.9 to 4.3), Carbo vegetabilis LR(+) 1.8 (95% CI: 0.8 to 4.0), and Staphysagria macrosperma LR(+) 1.5 (95% CI: 0.5 to 5.0). Overall, the findings corroborated the medicines' listing under the rubric in Kent's repertory. There was substantial evidence to link some of the enlisted medicines with the said rubric. Additional research involving a larger population is needed to address the potential confirmation bias.


  • Homeopathic Medicines Used as Prophylaxis in Kolkata during the COVID-19 Pandemic: A Community-Based, Cluster-Randomized Trial

    by Shyamal Kumar Mukherjee, Subhasish Ganguly, Satadal Das, Kalyan Kumar Chatterjee, Kisor Kumar Naskar, Samit Dey, Saptarshi Choudhury, Amitava Paul, Sasanka Sekhar Sarkar, Soumya Bhattacharyya, et al.

    Introduction There is some evidence that homeopathic treatment has been used successfully in previous epidemics, and currently some countries are testing homeoprophylaxis for the coronavirus disease 2019 (COVID-19) pandemic. There is a strong tradition of homeopathic treatment in India: therefore, we decided to compare three different homeopathic medicines against placebo in prevention of COVID-19 infections. Methods In this double-blind, cluster-randomized, placebo-controlled, four parallel arms, community-based, clinical trial, a 20,000-person sample of the population residing in Ward Number 57 of the Tangra area, Kolkata, was randomized in a 1:1:1:1 ratio of clusters to receive one of three homeopathic medicines (Bryonia alba 30cH, Gelsemium sempervirens 30cH, Phosphorus 30cH) or identical-looking placebo, for 3 (children) or 6 (adults) days. All the participants, who were aged 5 to 75 years, received ascorbic acid (vitamin C) tablets of 500 mg, once per day for 6 days. In addition, instructions on healthy diet and general hygienic measures, including hand washing, social distancing and proper use of mask and gloves, were given to all the participants. Results No new confirmed COVID-19 cases were diagnosed in the target population during the follow-up timeframe of 1 month—December 20, 2020 to January 19, 2021—thus making the trial inconclusive. The Phosphorus group had the least exposure to COVID-19 compared with the other groups. In comparison with placebo, the occurrence of unconfirmed COVID-19 cases was significantly less in the Phosphorus group (week 1: odds ratio [OR], 0.1; 95% confidence interval [CI], 0.06 to 0.16; week 2: OR, 0.004; 95% CI, 0.0002 to 0.06; week 3: OR, 0.007; 95% CI, 0.0004 to 0.11; week 4: OR, 0.009; 95% CI, 0.0006 to 0.14), but not in the Bryonia or Gelsemium groups. Conclusion Overall, the trial was inconclusive. The possible effect exerted by Phosphorus necessitates further investigation. Trial registration: CTRI/2020/11/029265.